 | • レポートコード：MRC2303B017 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の多嚢胞性卵巣症候群（PCOS）治療市場規模が予測期間中（2022～2027年）に年平均5.2％上昇すると推測されています。本調査書では、多嚢胞性卵巣症候群（PCOS）治療の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（薬剤、手術）分析、地域別（アメリカ、カナダ、メキシコ、フランス、ドイツ、イギリス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Abbott Laboratories、AbbVie Plc、Addex Therapeutics Ltd.、AstraZeneca PLC、Bayer AG、BIOCAD、Bristol-Myer Squibb Company、Crinetics Pharmaceuticals、EffRx, Inc.、Ferring BVなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の多嚢胞性卵巣症候群（PCOS）治療市場規模：治療別 - 薬剤における市場規模 - 手術における市場規模 ・世界の多嚢胞性卵巣症候群（PCOS）治療市場規模：地域別 - 北米の多嚢胞性卵巣症候群（PCOS）治療市場規模 アメリカの多嚢胞性卵巣症候群（PCOS）治療市場規模 カナダの多嚢胞性卵巣症候群（PCOS）治療市場規模 メキシコの多嚢胞性卵巣症候群（PCOS）治療市場規模 … - ヨーロッパの多嚢胞性卵巣症候群（PCOS）治療市場規模 ドイツの多嚢胞性卵巣症候群（PCOS）治療市場規模 イギリスの多嚢胞性卵巣症候群（PCOS）治療市場規模 フランスの多嚢胞性卵巣症候群（PCOS）治療市場規模 … - アジア太平洋の多嚢胞性卵巣症候群（PCOS）治療市場規模 中国の多嚢胞性卵巣症候群（PCOS）治療市場規模 日本の多嚢胞性卵巣症候群（PCOS）治療市場規模 インドの多嚢胞性卵巣症候群（PCOS）治療市場規模 … - 南米/中東の多嚢胞性卵巣症候群（PCOS）治療市場規模 南アフリカの多嚢胞性卵巣症候群（PCOS）治療市場規模 ブラジルの多嚢胞性卵巣症候群（PCOS）治療市場規模 アルゼンチンの多嚢胞性卵巣症候群（PCOS）治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The polycystic ovarian syndrome (PCOS) treatment market is expected to register a growth rate of 5.2% over the forecast period., 2022-2027.
The outbreak of COVID-19 had a significant impact on the healthcare industry. The polycystic ovarian syndrome (PCOS) treatment market is not immune to the effects of the pandemic, which had ramifications for many surgical procedures, including laparoscopic ovarian drilling. Various governments’ imposition of lockdown and social distancing restrictions to combat the COVID-19 pandemic outbreak resulted in the suspension of various operations, supply chain disruptions, stifling business growth, and the suspension of new developments, all of which negatively impacted the market. Moreover, according to the study titled “Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic’ published in the BMC Medicine in July 2020, Women with PCOS and other key risk factors for poor COVID-19 clinical outcomes suggest that this common female patient population may be at higher risk than expected if infected with SARS-CoV-2. Thus, the polycystic ovarian syndrome market was significantly impacted by COVID-19.
PCOS is a common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). According to the Centers for Disease Control & Prevention (CDC) May 2022, PCOS is the most common cause of female infertility. Also, as per a study titled “The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study,” published in the Frontier in Endocrinology in March 2022, PCOS (polycystic ovary syndrome) is the most common endocrine disorder in women of reproductive age, affecting 6–12% of them.
The increasing burden of PCOS and the unavailability of targeted therapy for PCOS in the market create a need to develop treatment therapies. The players in the market are currently focusing on the unmet market need and on strengthening their pipelines to leverage the opportunities; the commercialization of these robust pipelines is expected to propel market growth. For instance, in January 2020, Abbvie was working on a clinical trial for the chemical Elagolix, which was being evaluated for safety and efficacy in women with polycystic ovary syndrome. Elagolix’s safety and efficacy in women with polycystic ovarian syndrome are currently being evaluated in Phase 2 multicenter, double-blind, randomized, placebo-controlled study (PCOS). Such developments are expected to boost the market over the forecast period.
Also, there have been several initiatives by private and government firms to increase awareness about the disease, which is also expected to drive the market. For instance, in June 2020, the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes and Digestive and Kidney Diseases funded a study on ‘Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis’ and reported that polycystic ovary syndrome might have at least two different subtypes.
However, the side effects of symptomatic treatment drugs and the lack of approved drugs directly targeting PCOS disease drugs act as among the major restraints to the PCOS treatment market.
Polycystic Ovarian Syndrome Treatment Market Trends
Laparoscopic Ovarian Drilling is Expected to Hold Major Share Under Surgeries Over the Forecast Period
Laparoscopic ovarian drilling (LOD) is one of the most common surgeries doctors perform in critical conditions. Since women’s fertility problems are quite predominant because of PCOS, and response to medications weakens over time, the surgery performed via a thin microscope through the abdomen is majorly preferred across the geography. As per the study titled “Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome,” published in the Cochrane Library in July 2020, According to evidence, if the chance of a live birth following medical ovulation induction alone is 42%, the chance of a live birth following LOD is between 28% and 40%. The study suggested a high success rate in laparoscopic drilling in women, which is why it is most preferred. In addition, the cost-effective procedures drive patients toward this surgical procedure for easy treatment of the disease. Thus, it is estimated to have a significant share over the forecast period.
However, the COVID-19 pandemic has had ramifications for ways of working of various surgical procedures, including laparoscopic ovarian drilling. In May 2020, University of Birmingham Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery published their findings that the patients undergoing surgery after contracting coronavirus are at increased risk of postoperative death and are recommended to avoid all non-emergent surgeries. But, later, the regulatory bodies, to keep the normal surgical procedures going on, imposed a few guidelines specific to each specialty that must be implemented and followed for the surgeons to continue to provide safe and effective care to their patients during the COVID-19 pandemic. These issued guidelines have allowed healthcare providers to resume their surgery practices. Thus, it is expected that laparoscopic ovarian drilling procedures will also regain their normal growth in the future.
North America is Estimated to Have Largest Share in the Global Market
The rising prevalence of obesity and overweight people is leading to an increase in the number of people with PCOS, which is one of North America’s major drivers of market growth. Furthermore, as people become more aware of the benefits of regular checkups, the number of new cases diagnosed yearly in this region is rising. Obesity, considered a major risk factor for PCOS, has seen an upsurge during the pandemic. In September 2020, the Centers for Disease Control and Prevention (CDC) notified that adult obesity prevalence is increasing and racial and ethnic disparities persist owing to the current circumstances of work from home, lesser physical activities, and financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 %, including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia. The data by CDC revealed that there is a high prevalence of obesity in North American countries, which is going to increase the risk of PCOS and is anticipated to offer positive growth to the market.
The United States and Canada are highly advanced in procuring new technology and early release of drugs in the market. This region has a major player base and a strong product pipeline to propel market growth. For instance, in Jan 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome, which is expected to drive the market during the forecast period.
Additionally, in January 2020, Abbvie had an active clinical trial with the molecule Elagolix in the pipeline, which is being evaluated for its safety and efficacy in women with polycystic ovary syndrome. Currently, the company has a Phase 2, multicenter, double-blind, randomized, placebo-controlled study going on to assess the safety and efficacy of Elagolix in women with polycystic ovary syndrome (PCOS).
The need to ease the treatment and procedures has evolved significantly in the past decade, pushing several R&D investments and venture partners funding for pharmaceutical companies in this region, thus driving the market growth.
Polycystic Ovarian Syndrome Treatment Market Competitor Analysis
The major market players are focusing on symptomatic treatments; several have their drugs in clinical trials but are not approved for marketing. There is a growing focus on surgeries, and many medical devices are focused on the same. Some of the major players in the market are Bayer AG, Ferring BV, Merck KGaA, Novartis, Pfizer, Takeda, and Teva Pharmaceutical Industries Limited, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Burden of PCOS
4.2.2 Growth in Initiatives by Government and Private Players to Raise Awareness
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Treatment
4.3.2 Lack of FDA Approved Drugs Specific to Polycystic Ovarian Syndrome (PCOS)
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment
5.1.1 Drug Class
5.1.1.1 Contraceptives
5.1.1.2 Insulin-sensitizing Agent
5.1.1.3 Antidepressants
5.1.1.4 Anti-obesity
5.1.1.5 Other Drug Classes
5.1.2 Surgery
5.1.2.1 Ovarian Wedge Resection
5.1.2.2 Laparoscopic Ovarian Drilling
5.1.2.3 Other Surgeries
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 France
5.2.2.2 Germany
5.2.2.3 United Kingdom
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AbbVie Plc
6.1.3 Addex Therapeutics Ltd.
6.1.4 AstraZeneca PLC
6.1.5 Bayer AG
6.1.6 BIOCAD
6.1.7 Bristol-Myer Squibb Company
6.1.8 Crinetics Pharmaceuticals
6.1.9 EffRx, Inc.
6.1.10 Ferring BV
6.1.11 Johnson and Johnson
6.1.12 Merck KGaA
6.1.13 Mylan N.V
6.1.14 Neurocrine Biosciences, Inc.,
6.1.15 Novartis International AG
6.1.16 Pfizer Inc.
6.1.17 Sanofi SA
6.1.18 Shire PLC
6.1.19 Takeda Pharmaceutical Company Limited
6.1.20 Teva Pharmaceutical Industries Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS